Itonic Holdings Ltd. (NASDAQ:ITOC) Stock Short Interest Climbs 228.6%

Itonic Holdings Ltd. (NASDAQ:ITOC) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 206,400 shares, a growth of 228.6% from the September 15th total of 62,815 shares. Currently, 19.4% of the shares of the company are short sold. Based on an average trading volume of 1,701,703 shares, the short-interest ratio is presently 0.1 days.

Itonic Stock Performance

ITOC traded up $0.05 during trading on Friday, hitting $4.07. The stock had a trading volume of 14,110 shares, compared to its average volume of 67,873. The company has a 50 day moving average price of $4.68 and a 200-day moving average price of $4.95. Itonic has a one year low of $3.42 and a one year high of $18.40.

Itonic (NASDAQ:ITOC) last posted its quarterly earnings data on Wednesday, September 30th. The company reported ($0.75) earnings per share for the quarter. The business had revenue of $0.05 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings cut Itonic from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Itonic

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.